Microbiological characteristics of the probiotic strains B. longum BB536 and L. rhamnosus HN001 used in combination

Minerva Gastroenterologica e Dietologica

Volumn 61, Issue 4, 2015, Pages 191-197

  Inturri, R ^a   Stivala, A ^a   Blandino, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

BIF protein; Bifidobacterium longum; Drug antagonism; Drug therapy, combination; Lactobacillus rhamnosus

Indexed keywords

BILE SALT; PROBIOTIC AGENT; BILE ACID;

AGAR DIFFUSION; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM ADHERENCE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM BB536; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS RHAMNOSUS HN001; NONHUMAN; PH; QUANTITATIVE ANALYSIS; SURVIVAL RATE; CELL LINE; CHEMISTRY; INTESTINE; INTESTINE MUCOSA; MICROBIOLOGY; PHYSIOLOGY;

BACTERIAL ADHESION; BIFIDOBACTERIUM LONGUM; BILE ACIDS AND SALTS; CELL LINE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; INTESTINES; LACTOBACILLUS RHAMNOSUS; PROBIOTICS;

EID: 84962581452     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Collado MC, Meriluotob J, Salminen S. In vitro analysis of probiotic strain combinations to inhibit pathogen adhesion to human intestinal mucus. Food Res Int 2007;40:629-36.
2. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to Lactobacillus rhamnosus HN001 (AGAL NM97/09514) and decreasing potentially pathogenic intestinal microorganisms (ID 908) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA Journal 2009;7(9):1244. [11 pp.], doi:10.2903/j.efsa.2009.1244 [Internet]. Available from www.efsa.europa.eu [cited 2015, Oct. 5].
3. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastrointestinal microorganisms (ID 3005) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2041. [18 pp.].
4. EFSA Journal 2011;9(4):2041 doi:10.2903/j.efsa.2011.2041 [Internet]. Available from www.efsa.europa.eu/efsajournal [cited 2015, Oct. 5]
5. ® modifies subpopulations of fecal lactobacilli and Clostridium difficile in the elderly. Age 2012;34:133-43
6. Odamaki T, Sugahara H, Yonezawa S, Yaeshima T, Iwatsuki K, Tanabe S, et al. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. Anaerobe 2012;18:14-8
7. Ferdousi R, Rouhi M, Mohammadi R, Mortazavian AM, Khosravi-Darani K, Homayouni Rad A, Evaluation of probiotic survivability in yogurt exposed to cold chain interruption. Iran J Pharm Res 2013;12(Suppl):139-44.
8. Gagic D, Wen W, Collett MA, Rakonjac J. Unique secreted-surface protein complex of Lactobacillus rhamnosus, identified by phage display. Microbiologyopen 2013;2:1-17.
9. Izquierdo E, Medina M, Ennahar S, Marchioni E, Sanz Y. Resistance to simulated gastrointestinal conditions and adhesion to mucus as probiotic criteria for Bifidobacterium longum strains. Curr Microbiol 2008;56:613-8.
10. Muñoz-Quezada S, Chenoll E, Vieites JM, Genovés S, Maldonado J, Bermúdez-Brito M, et al. Isolation, identification and characterisation of three novel probiotic strains (Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036) from the faeces of exclusively breast-fed infants. British J Nutr 2013;109:51-62.
11. Devi SM, Archer AC, Halami PM. Screening, characterization and in vitro evaluation of probiotic properties among lactic acid bacteria through comparative analysis. Probiotics Antimicrob Proteins 2015;7:181-92.
12. Rautava S, Walker WA. Commensal bacteria and epithelial cross talk in the developing intestine. Curr Gastroenterol Rep 2007;9:385-92.
13. Guglielmetti S, Tamagnini I, Mora D, Minuzzo M, Scarafoni A, Arioli S, et al. Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifidum to Caco-2 cells. Appl Environ Microbiol 2008;74:4695-702.
14. Gill SH and Rutherfurd KJ. Probiotic supplementation to enhance natural immunity in the elderly: effects of a newly characterized immunostimulatory strain Lactobacillus rhamnosus HN001 (DR20TM) on leucocyte phagocytosis. Nutr Res 2001;21:183-9.
15. Ruas-Madiedo P, Gueimonde M, Margolles A, de los Reyes-Gavilán CG, Salminen S. Exopolysaccharides produced by probiotic strains modify the adhesion of probiotics and enteropathogens to human intestinal mucus. J Food Prot 2006;69:2011-5.
16. Inturri R, Tiralongo A, Tempera G, Sinatra F, Blandino G. Study on the Adhesion Characteristics of Bifidobacterium spp. strains on HT-29 Human Epithelial Cell Line. Proceedings of the 113th General meeting American Society for Microbiology; 2013 May 18-21; Denver, Colorado, U. S. DOI:10.13l40/RG.2.1.1352.2644
17. Inturri R, Stivala A, Sinatra F, Morrone R, Blandino G. Scanning electron microscopy observation of adhesion properties of Bifidobacterium mgum W11 and chromatographic analysis of its exopolysaccaride. Food and Nutr Sci 2014;5:1787-92.
18. Abdel-Daim A, Hassouna N, Hafez M, Ashor MS, Aboulwafa MM. Antagonistic activity of Lactobacillus isolates against Salmonella typhi in vitro. Biomed Res Int 2013;2013:680605.
19. Prasad J, Gill H, Smart J. Selection and characterization of Lactobacillus and Bifidobacterium strains for use as probiotics. Int Dairy J 1998;8:993-1002.
20. Doleyres Y, Fliss I, Lacroix C. Increased stress tolerance of Bifidobacterium longum and Lactococcus lactis produced during continuous mixed-strain immobilized-cell fermentation. J Appl Microbiol 2004;97:527-39.
21. Simpson PJ, Fitzgerald GF, Stanton C, Ross R. The evaluation of a mupirocin-based selective medium for the enumeration of bifidobacteria from probiotic animal feed. P J Microbiol Methods 2004;57:9-16.
22. de los Reyes-Gavilán CG, Suárez A, Fernández-García M, Margolles A, Gueimonde M, Ruas-Madiedo P. Adhesion of bile-adapted Bifidobacterium strains to the HT29-MTX cell line is modified after sequential gastrointestinal challenge simulated in vitro using human gastric and duodenal juices. Res Microbiol 2011;162:514-9.
23. Serafini F, Strati F, Ruas-Madiedo P, Turroni F, Foroni E, Duranti S, et al. Evaluation of adhesion properties and antibacterial activities of the infant gut commensal Bifidobacterium bifidum PRL2010. Anaerobe 2013;21:9-17.
24. FAO/WHO, 2006, Probiotics in Food. Health and Nutritional Properties and Guidelines for Evaluation, FAO Food and Nutritional paper No. 85, (ISBN 92-5-105513-0).
25. Tanaka H, Hashiba H, Kok J, Mierau I. Bile salt hydrolase of Bifidobacterium longum biochemical and genetic characterization. Appl Environ Microbiol 2000;66:2502-12.
26. Blandino G, Fazio D, and Di Marco R. Probiotics: overview of microbiological and immunological characteristics. Expert Rev Anti Infect Ther 2008;6:497-508.
27. Ventura M, Turroni F, Motherway MO, MacSharry J, van Sinderen D. Host-microbe interactions that facilitate gut colonization by commensal bifidobacteria. Trends Microbiol 2012;20:467-76.
28. Turroni F, Duranti S, Bottacini F, Guglielmetti S, Van Sinderen D, Ventura M. Bifidobacterium bifidum as an example of a specialized human gut commensal. Front Microbiol 2014a; 5:437.
29. Turroni F, Ventura M, Buttó LF, Duranti S, O'Toole PW, Motherway MO, et al. Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective. Cell Mol Life Sci 2014b; 71:183-203.
30. Gond PK, Prasad J, Smart J, Gill HS. In vitro adherence perties of lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int J Food Microbiol 2001;67:207-16.
31. Ali QS, Farid AJ, Kabeir BM. Adhesion properties of Bifidobacterium pseudocatenulatum G4 and Bifidobacterium longum BB536 on HT-29 human epith "al cell line at different times and pH. WASET 2009;49:149-53.
32. Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, Kelly WJ et al. lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol 2010;9:10:316.
33. Hidalgo-Cantabrana C, Nikolic M, López P, Suárez A, Miljkovic M, Kojic M et al. Exopolysaccharide-producing Bifidobacterium animalis subsp. lactis strains and their polymers elicit different responses on immune cells from blood and gut associated lymphoid tissue. Anaerobe 2014;26:24-30.
34. Inturri R, Santagati M, Scillato M, Stefani S, Blandino. Caratterizzazione molecolare e profilo biochimico di ceppi di Bifidobacterium spp. Utilizzati in prodotti probiotici. Proceedings of X Congresso Nazionale della Società Italiana di Microbiologia Farmaceutica (SIMiF) 2014a. 6-7 Giugno; Chieti, Italia.